文献速递免疫规划

不同剂型sIPV序贯接种bOPV(Ⅰ+Ⅲ型)的免疫原性与安全性比较

[Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (Ⅰ+Ⅲ) in different dosage forms].
PubMed 文献 · Zhonghua Yu Fang Yi Xue Za Zhi · 2018-01-01

2015年9月至2016年6月在广西柳州开展随机、盲法、单中心、平行对照试验,比较≥2月龄婴儿1sIPV+2bOPV与2sIPV+1bOPV两种序贯程序下bOPV糖丸与液体剂型的安全性和免疫原性。结果显示同一序贯程序下两种剂型安全性及免疫原性无显著差异;同一剂型下2sIPV组Ⅱ型、Ⅲ型中和抗体GMT及Ⅱ型阳转率高于1sIPV组。

要点

  • 同一序贯程序下bOPV糖丸与液体剂型不良反应及严重不良反应发生率无显著差异。
  • 同一序贯程序下两种剂型Ⅰ、Ⅱ、Ⅲ型脊灰抗体阳转率均无显著差异。
  • 同一剂型下2sIPV组Ⅱ型、Ⅲ型中和抗体GMT高于1sIPV组,Ⅱ型阳转率更高。

核心结论

  • 相同序贯免疫程序中,bOPV糖丸剂型与液体剂型在≥2月龄婴儿中均具有良好的安全性和免疫原性。
  • 相同剂型不同免疫程序中,2sIPV组较1sIPV组产生更高的血清中和抗体水平,尤其表现在Ⅱ型、Ⅲ型免疫后抗体GMT水平。

研究设计与样本

  • 2015年9月至2016年6月在广西柳州开展的随机、盲法、单中心、平行对照试验。
  • ≥2月龄健康婴儿分为1sIPV+2bOPV和2sIPV+1bOPV序贯程序,每种程序再按bOPV剂型分为糖丸组与液体组,每组100名。
  • 按0、28、56 d免疫程序共接种3剂;记录至少接种1剂次受试者399名不良反应;全程免疫后28 d采集排除脱落者和违背试验方案者共350名血样。

主要发现

  • 全部不良反应发生率:1sIPV+2bOPV糖丸组79%(79/100)、1sIPV+2bOPV液体组76%(76/100)、2sIPV+1bOPV糖丸组80%(79/99)、2sIPV+1bOPV液体组74%(74/100),χ²=1.23,P=0.747。
  • 严重不良反应发生率:1sIPV+2bOPV糖丸组6%(6/100)、1sIPV+2bOPV液体组5%(5/100)、2sIPV+1bOPV糖丸组6%(6/99)、2sIPV+1bOPV液体组4%(4/100),χ²=0.57,P=0.903,均未认为与接种相关。
  • Ⅱ型脊灰抗体阳转率:1sIPV+2bOPV糖丸组47%(41/87)、1sIPV+2bOPV液体组57%(47/83)、2sIPV+1bOPV糖丸组80%(70/88)、2sIPV+1bOPV液体组79%(73/92),χ²=31.56,P<0.001。
  • Ⅰ型脊灰抗体GMT:1sIPV+2bOPV糖丸组4539.68、1sIPV+2bOPV液体组6243.43、2sIPV+1bOPV糖丸组6819.53、2sIPV+1bOPV液体组7916.29(F=25.87,P<0.001);Ⅱ型GMT分别为12.98、10.54、63.75、84.21(F=8.68,P=0.034);Ⅲ型GMT分别为1172.55、1416.03、2648.89、3250.75(F=14.50,P=0.002)。
  • Ⅰ型脊灰抗体阳转率:1sIPV+2bOPV糖丸组99%(86/87)、1sIPV+2bOPV液体组100%(83/83)、2sIPV+1bOPV糖丸组99%(87/88)、2sIPV+1bOPV液体组99%(91/92),χ²=0.94,P=0.815;Ⅲ型分别为100%(87/87)、99%(82/83)、100%(88/88)、99%(91/92),χ²=2.02,P=0.568。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare the safety and immunogenicity of two different sequential schedules of inactivated poliomyelitis vaccine made from Sabin strain (sIPV) followed by typeⅠ+Ⅲ bivalent oral poliovirus vaccine (bOPV) in Drug Candy (DC) form or liquid dosage form). Methods: This randomized, blinded, single center, parallel-group controlled trial was done from September 2015 to June 2016 in Liuzhou, Guangxi province. Healthy infants aged ≥2 months were eligible for enrollment and divided into 1sIPV+2bOPV or 2sIPV+1bOPV sequential schedules. According to the bOPV dosage form each sequential schedules, the subjects again were divided into drug candy(DC) form or liquid dosage form group, being 1sIPV+bOPV (DC)/1sIPV+2bOPV(liquid)/2sIPV+1bOPV(DC)/2sIPV+1bOPV(liquid). According to 0, 28, 56 d immunization schedule, Each group were given 3 doses. We recorded adverse events during the clinical trial (399 participants who receive at least one dose). 28 days post-Dose 3, we receive a total of 350 blood samples (excluding the quitters or subjects against trial plan), using cell culture trace against polio virus neutralization test Ⅰ, Ⅱ, Ⅲ neutralizing antibody (GMT), calculating the antibody positive rate.PolioⅠ,Ⅱand Ⅲ antibody titers were assessed by virus-neutralizing antibody assay and the seroconversion (4-fold increase in titer) from pre-Dose 1 to 28 days post-Dose 3 was calculated (total 350 samples) . Results: During the vaccination, the incidence of AEs in 1sIPV+2bOPV(DC), 1sIPV+2bOPV (liquid), 2sIPV+1bOPV(DC), 2sIPV+1bOPV (liquid) group were 79%, 76%, 80% and 74% (χ(2)=1.23, P=0.747) , respectively. The severe AEs in groups were 6%, 5%, 6% and 4% (χ(2)=0.57, P=0.903) , respectively, and none was considered to be vaccination related. 28 days after 3(rd) vaccination, the seroconversion rates in 1sIPV+2bOPV (DC), 1sIPV+2bOPV (liquid), 2sIPV+1bOPV (DC), 2sIPV+1bOPV (liquid) group, were 99%, 100%, 99% and 99% (χ(2)=0.94, P=0.815) , respectively, for type Ⅰ poliovirus; and 47%, 57%, 80%, 79% (χ(2)=31.56, P<0.001) , respectively, for type Ⅱ; and were 100%, 99%, 100%, 99% (χ(2)=2.02, P=0.568) , respectively, for type Ⅲ. In each group, the GMT of antibody against poliovirus typeⅠ were 4 539.68, 6 243.43, 6 819.53 and 7 916.29 (F=25.87, P<0.001) , respectively; Type Ⅱ were 12.98, 10.54, 63.75 and 84.21 (F=8.68, P=0.034) , respectively; Type Ⅲ were 1 172.55, 1 416.03, 2 648.89 and 3 250.75 (F=14.50, P=0.002) , respectively. Conclusion: On the same sequential schedules, there was no significant difference between the dosage forms, all of them showed good safety and immunogenicity. In the same dosage forms with different sequential schedules, the seroconversion rate was higher in 2 dose sIPV group than the 1 dose sIPV group, especially at the neutralizing antibody GMT level against polio type Ⅱ and Ⅲ after vaccination. 目的: 比较Ⅰ+Ⅲ型脊髓灰质炎减毒活疫苗(人二倍体细胞)(bOPV)糖丸和液体剂型与Sabin株脊髓灰质炎灭活疫苗(sIPV)联合序贯免疫接种在≥2月龄婴儿中的免疫原性和安全性。 方法: 于2015年9月至2016年6月,采用随机、盲法、单中心、平行对照设计,选择广西柳州市≥2月龄的婴儿为研究对象,将其分为1sIPV+2bOPV和2sIPV+1bOPV组,每种序贯免疫程序按bOPV剂型不同再分为糖丸剂型组与液体剂型组,即1sIPV+2bOPV糖丸组、1sIPV+2bOPV液体组、2sIPV+1bOPV糖丸组、2sIPV+1bOPV液体组,每组100名,按照0、28、56 d的免疫程序,共接种3剂。记录至少接种1剂次受试者(399名)不良反应事件;全程免疫后28 d,采集排除脱落者和违背试验方案者(共350名)血样,采用细胞培养微量中和试验测定抗脊灰病毒Ⅰ、Ⅱ、Ⅲ型中和抗体滴度(GMT),计算抗体阳转率,并对其进行统计学分析。 结果: 1sIPV+2bOPV糖丸组、1sIPV+2bOPV液体组、2sIPV+1bOPV糖丸组、2sIPV+1bOPV液体组全部不良反应发生率分别为79%(79/100)、76%(76/100)、80%(79/99)和74%(74/100)(χ(2)=1.23,P=0.747);严重不良反应发生率分别为6%(6/100)、5%(5/100)、6%(6/99)和4%(4/100)(χ(2)=0.57,P=0.903)。全程免疫后,1sIPV+2bOPV糖丸组、1sIPV+2bOPV液体组、2sIPV+1bOPV糖丸组、2sIPV+1bOPV液体组Ⅰ型脊灰抗体阳转率分别为99%(86/87)、100%(83/83)、99%(87/88)、99%(91/92)(χ(2)=0.94,P=0.815),Ⅱ型分别为47%(41/87)、57%(47/83)、80%(70/88)、79%(73/92)(χ(2)=31.56,P<0.001),Ⅲ型分别为100%(87/87)、99%(82/83)、100%(88/88)、99%(91/92)(χ(2)=2.02,P=0.568);Ⅰ型脊灰抗体GMT分别为4 539.68、6 243.43、6 819.53、7 916.29(F=25.87,P<0.001),Ⅱ型分别为12.98、10.54、63.75、84.21(F=8.68,P=0.034),Ⅲ型分别为1 172.55、1 416.03、2 648.89、3 250.75(F=14.50,P=0.002)。 结论: 相同序贯免疫程序中,bOPV糖丸剂型与液体剂型在≥2月龄的婴儿中均具有良好的安全性和免疫原性;相同剂型不同免疫程序中,2sIPV组较1sIPV组产生更高的血清中和抗体水平,尤其表现在Ⅱ型、Ⅲ型免疫后抗体GMT水平。.

来源:Zhonghua Yu Fang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ye H, Huang T, Ying ZF, et al. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (Ⅰ+Ⅲ) in different dosage forms]. Zhonghua Yu Fang Yi Xue Za Zhi. 2018. PMID: 29334707. doi:10.3760/cma.j.issn.0253-9624.2018.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。